Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Fosun Pharma's Fumaining (luvometinib), a MEK 1/2 inhibitor, wins NMPA approval for pediatric Langerhans cell histiocytosis
Small molecule, cancer, MEK inhibitor, Langerhans cell histiocytosis, pediatric, rare disease - Read more

Jazz Pharmaceuticals, AbCellera collaborate on T cell engagers for GI cancers, up to $2.46B
Research collaboration, oncology, antibody, milestone payments, royalties - Read more

Niowave, Ratio Therapeutics sign Actinium-225 supply agreement to advance targeted alpha therapies
Supply agreement, oncology, radiopharmaceuticals, manufacturing, targeted alpha therapy - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Henlius completes Ph3 trial of HLX04-O (bevacizumab) targeting VEGF for wet age-related macular degeneration
Antibody, ophthalmic disease, monoclonal antibody, wet age-related macular degeneration, VEGF, bevacizumab biosimilar - Read more

Luye Pharma Group's LY03015 (VMAT2 inhibitor) hits 76.5% response rate in Ph2 tardive dyskinesia trial
Small molecule, neurological, VMAT2 inhibitor, tardive dyskinesia, Sigma-1R activator - Read more

Vedana Therapeutics launches with $46M Series A to develop PACAP-targeting migraine therapies for patients unresponsive to CGRP drugs
Neurology, antibody, migraine, PACAP, preclinical - Read more

Gero closes $17M round, totaling $34M, advancing AI-driven ageing drug discovery platform
AI-driven, drug discovery, ageing, small molecule, platform technology, preclinical - Read more

MultiValent Biotherapies raises $27M Series A, advancing targeted prostate cancer drug conjugate MVB-101
Oncology, drug conjugate, prostate cancer, clinical-stage, targeted therapy - Read more

SpliSense raises up to $13M, advancing inhaled ASO therapy for cystic fibrosis
Clinical-stage, antisense oligonucleotide, cystic fibrosis, pulmonary disease, rare disease - Read more

Dioseve raises ~$7M in funding to advance ReproNest iPS cell-derived fertility technology
Reproductive medicine, cell therapy, iPS cell, fertility, preclinical - Read more

Emmecell closes undisclosed funding round to advance magnetic cell delivery ophthalmic platform
Clinical-stage, cell therapy, ophthalmology, magnetic cell delivery, regenerative medicine - Read more

Novo Nordisk opens Czech plant for next-gen drug proteins, unveils $29M China facility upgrade
GLP-1, diabetes & obesity, manufacturing expansion, operational - Read more

PwC declares biopharma M&A ecosystem fully recovered, predicting continued precision-science dealmaking through year-end
Biopharma ecosystem, oncology, major transaction, strategic, financial - Read more

Altaris acquires Simulations Plus for $375M, plans merger with Chemical Computing Group to expand AI drug development
AI drug development, drug discovery, major transaction, strategic - Read more

Eli Lilly to acquire 4E Therapeutics, expanding non-opioid pain pipeline with MNK inhibitor treatments
Small molecule, pain, strategic, major transaction - Read more

Verge Labs launches "virtual biopsy" AI model to predict brain therapy response, targeting neurology's 94% trial failure rate
AI/machine learning platform, neurological, clinical trials, strategic - Read more

Moderna's mRNA flu shot mFlusiva gets favorable FDA review ahead of critical advisory committee vote
mRNA vaccine, infectious disease, regulatory, financial - Read more

FDA, MHRA launch transatlantic liaison program to accelerate regulatory collaboration on innovative medicines and AI
Regulatory collaboration, innovative medicines, medical devices, artificial intelligence - Read more

uniQure plans Q3 BLA submission for Huntington's gene therapy after FDA reverses course on accelerated approval
Gene therapy, neurological, rare disease, regulatory, strategic - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Express Scripts, PCMA sue to block Tennessee law separating PBMs from pharmacy ownership
Pharmacy benefit management, healthcare policy, regulatory, competitive, operational - Read more

Be Biopharma discontinues Ph1/2 trial of BE-101 B cell therapy targeting factor IX deficiency in hemophilia B
Cell therapy, rare disease, B cell therapy, hemophilia B, factor IX, autologous cell therapy - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here